Related Experiment Video
Updated: Aug 14, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Management of Hepatitis C in Children - A New Paradigm
Ujjal Poddar1, D V Umesh Reddy2
1Department of Pediatric Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh. Correspondence to: Dr Ujjal Poddar, Professor and Head, Department of Pediatric Gastroenterology, SGPGIMS, Raebareli Road, Lucknow 226 014, Uttar Pradesh. ujjalpoddar@hotmail.com.
Insights
Direct-acting antivirals (DAAs) have revolutionized hepatitis C (HCV) treatment in children, offering high efficacy and safety. Current DAA regimens simplify management for pediatric HCV infection, marking a significant advancement.
Area of Science:
- Pediatric Hepatology
- Virology
- Pharmacotherapy
Background:
- Hepatitis C virus (HCV) infection in children historically presented treatment challenges with interferon-based regimens.
- Previous treatments for pediatric HCV infection showed limited efficacy (58% SVR) and significant side effects (52%).
Approach:
- A literature search was conducted on PubMed, focusing on pediatric HCV (ages 0-18) treatment options.
- The review analyzes the evolution of HCV management from older therapies to modern direct-acting antivirals (DAAs).
Key Points:
- Direct-acting antivirals (DAAs) demonstrate high efficacy (92%-100% SVR12) and excellent safety profiles in children over three years old.
- DAA regimens represent the current standard of care for pediatric hepatitis C infection.
- Treatment simplification is a key outcome of DAA availability for pediatric HCV.
Conclusions:
- DAA therapy has transformed pediatric HCV management, making treatment simpler and more effective.
- Eliminating HCV in children requires continued DAA accessibility, public awareness, and improved screening strategies.
Introduction:
With the advent of direct-acting antivirals (DAAs), the past decade has seen a paradigm shift in the management of hepatitis C (HCV) infection in children. In this review, we summarize the various treatment options for pediatric HCV infection, highlighting the recent changes in the management.
Methods:
A literature search was performed using the PubMed database with the relevant keywords. Filters included were human, ages 0-18 years, and the English language.
Results:
Initial phase of HCV treatment using conventional or pegylated interferon and ribavirin combination regimens yielded poor outcomes in children, especially in genotypes 1 and 4, with an overall sustained virologic response of 58%. Also, treatment with interferon and ribavirin combination was associated with significant side effects in up to 52% of those treated. Presently, various combinations of direct-acting antivirals (DAAs) have been approved in children above three years of age with documented evidence of high efficacy (SVR12 of 92% to 100%) and excellent safety, and the current standard of care.
Conclusion:
With various DAA regimens now being approved for children above three years of age, the treatment of active HCV infection (HCV-RNA positive) in children has become simple. Besides the effectiveness of DAA therapy, public awareness about HCV transmission, better screening, and making the DAAs available at a subsidized price in the public sectors are necessary to eliminate HCV infection in India.
More Related Videos
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Cystic Fibrosis: Management
Sinus disease and chronic...
Retrovirus Life Cycles